Neuromuscular DiseasesNeuromuscular DiseasesНервно-мышечные болезни2222-87212413-0443Publishing House ABV Press30010.17650/2222-8721-2018-8-4-12-18LECTURES AND REVIEWSЛЕКЦИИ И ОБЗОРЫAmyotrophic lateral sclerosis: pathogenetic mechanisms and new approaches to pharmacotherapy (literature review)Боковой амиотрофический склероз: механизмы патогенеза и новые подходы к фармакотерапии (обзор литературы)https://orcid.org/0000-0002-4441-1165AlekseevaT. M.АлексееваТ. М.
Russian Federation

2 Akkuratova St., Saint Petersburg 197341, Russia

197341 Санкт-Петербург, ул. Аккуратова, 2

StuchevskayaT. R.СтучевскаяТ. Р.
Russian Federation

5 Uchebny Lane, Saint Petersburg 194354, Russia

194354 Санкт-Петербург, Учебный пер., 5

https://orcid.org/0000-0003-3379-9069DemeshonokV. S.ДемешонокВ. С.
Russian Federation

47 Piskarevsky Ave., Saint Petersburg 195067, Russia

Вера Сергеевна Демешонок 

 

195067 Санкт-Петербург, просп. Пискаревский, 47

vera3009.85@mail.ruV.A. Almazov National Medical Research Center, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр им. В.А. Алмазова» Минздрава РоссииCity Multi-Speciality Hospital No. 2СПб ГБУЗ «Городская многопрофильная больница № 2»North-Western State Medical University n. a. I.I. Mechnikov, Ministry of Health of RussiaФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава России120120198412181101201911012019Copyright ©; 2019, Alekseeva T.M., Stuchevskaya T.R., Demeshonok V.S.Copyright ©; 2019, Алексеева Т.М., Стучевская Т.Р., Демешонок В.С.2019Alekseeva T.M., Stuchevskaya T.R., Demeshonok V.S.Алексеева Т.М., Стучевская Т.Р., Демешонок В.С.https://creativecommons.org/licenses/by/4.0https://nmb.abvpress.ru/jour/article/view/300

Amyotrophic lateral sclerosis is a neurodegenerative disease, resulting in the loss of self-service and death of the middle-aged and elderly people. In the last 2 decades, significant progress has been made in the study of the pathogenesis of this disease. Two known drugs (riluzole and edaravone) have been approved by the Food and Drug Administration for treatment of amyotrophic lateral sclerosis. The efficacy of these drugs is extremely low, so clinical trials of new drugs are ongoing all over the world. This review discusses the current achievements and future directions of therapy of this disease.

Боковой амиотрофический склероз – тяжелое нейродегенеративное заболевание, обусловленное поражением двигательных нейронов головного и спинного мозга и приводящее к тяжелой инвалидизации и смерти через 3–5 лет с момента его дебюта. В последние 2 десятилетия достигнут значительный прогресс в изучении патогенетических механизмов развития данного заболевания. Рилузол и эдаравон, одобренные Управлением по контролю за качеством пищевых продуктов и лекарственных препаратов (Food and Drug Administration) в 2003 и 2017 гг. для лечения бокового амиотрофического склероза, оказались недостаточно эффективны, поэтому продолжается поиск новых препаратов. В статье обсуждаются современные достижения и некоторые перспективные направления патогенетической терапии бокового амиотрофического склероза.

motor neuron diseaseamyotrophic lateral sclerosispathogenetic therapyclinical trialriluzoleedaravonenuedextamasitinibболезнь моторных нейроновбоковой амиотрофический склерозпатогенетическая терапияклинические исследованиярилузолэдаравоннудекстамаситинибLogroscino G., Traynor B.J., Hardiman O. et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry 2010;81(4):385–90. DOI: 10.1136/jnnp.2009.183525. PMID: 19710046.Marin B., Boumédiene F., Logroscino G. et al. Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. Int J Epidemiol 2017;46(1): 57–74. DOI: 10.1093/ije/dyw061. PMID: 27185810.Chio A.G., Logroscino G., Traynor B.J. et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 2013;41(2):118–30. DOI: 10.1159/000351153. PMID: 23860588.Lacomblez L., Bensimon G., Leigh P.N. et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Аmyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996;347(9013):1425–31. DOI: 10.5555/uri:pii:S0140673696916803. PMID: 8676624.Riviere M., Meininger V., Zeisser P., Munsat T. An analysis of extended survival in patients with ALS treated with riluzole. Arch Neurol 1998;55(4):526–8. DOI: 10.1001/archneur.55.4.526. PMID: 9561981.Brooks B.R., Belden D.S., Roelke K. et al. Survival in non-riluzole treated amyotrophic lateral sclerosis (ALS) – motor neuron disease (MND) patients with disease onset before and since 1996 is identical: a clinic-based epidemiological study. Amyotroph Lateral Scler Other Motor Neuron Disord 2001;2(Suppl 2):60–1.Turner M.R., Bakker M., Sham P. et al. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2002;3(1):15–21. DOI: 10.1080/146608202317576499. PMID: 12061944.Al-Chalabi A., Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol 2013;9(11):617–28. DOI: 10.1038/nrneurol.2013.203. PMID: 24126629.Vasenina E.E., Levin O.S. Oxidative stress in the pathogenesis of neurodegenerative diseases: possibilities of therapy. Sovremennaya terapiya v psikhiatrii i nevrologii = Modern Therapy in Psychiatry and Neurology 2013;3(4):39–46. (In Russ.).Васенина Е.Е., Левин О.С. Окислительный стресс в патогенезе нейродегенеративных заболеваний: возможности терапии. Современная терапия в психиатрии и неврологии 2013;3(4): 39–46.King A.E., Woodhouse A., Kirkcaldie M.T., Vickers J.C. Excitotoxicity in ALS: Overstimulation, or overreaction? Exp Neurol 2016;275:162–71. DOI: 10.1016/j.expneurol.2015.09.019. PMID: 26584004.Bräuer S., Zimyanin V., Hermann A. Prion-like properties of disease-relevant proteins in amyotrophic lateral sclerosis. J Neural Transm (Vienna) 2018;125(4):591–613. DOI: 10.1007/s00702-018-1851-y. PMID: 29417336.Ramesh N., Pandey U.B. Autophagy dysregulation in ALS: When protein aggregates get out of hand. Front Mol Neurosci 2017;10:263. DOI: 10.3389/fn-mol.2017.00263. PMID: 28878620.Hooten K.G., Beers D.R., Zhao W., Appel S.H. Protective and toxic neuroinflammation in amyotrophic lateral sclerosis. Neurotherapeutics 2015;12(2):364–75. DOI: 10.1007/s13311-014-0329-3. PMID: 25567201.Ugras S.E., Shorter J. RNA-binding proteins in amyotrophic lateral sclerosis and neurodegeneration. Neurol Res Int 2012;2012:432780. DOI: 10.1155/2012/432780. PMID: 22919483.De Vos K.J., Hafezparast M. Neurobiology of axonal transport defects in motor neuron diseases: Opportunities for translational research? Neurobiol Dis 2017;105:283–99. DOI: 1016/j. nbd.2017.02.004. PMID: 28235672.Smith E.F., Shaw P.J., De Vos K.J. The role of mitochondria in amyotrophic lateral sclerosis. Neurosci Lett 2017 Jun 30. Available at: https://www.sciencedirect.com/science/article/pii/S030439401730544X?via%3Dihub. DOI: 10.1016/j.neulet.2017.06.052. PMID: 28669745.Al-Chalabi A., Calvo A., Chio A. et al. Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol 2014;13(11):1108–13. DOI: 10.1016/S1474-4422(14)70219-4. PMID: 25300936.Chia R., Chiò A., Traynor B.J. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol 2018;17(1):94–102. DOI: 10.1016/S1474-4422(17)30401-5. PMID: 29154141.Maurel C., Dangoumau A., Marouillat S. Causative genes in amyotrophic lateral sclerosis and protein degradation pathways: a link to neurodegeneration. Mol Neurobiol 2018;55(8);6480–99. DOI: 10.1007/s12035-017-0856-0. PMID: 29322304.Blokhuis A.M., Groen E.J., Koppers M. et al. Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol 2013;125(6):777–94. DOI: 10.1007/s00401-013-1125-6. PMID: 23673820.Liu J., Wang F. Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications. Front Immunol 2017;8:1005. DOI: 10.3389/fimmu.2017.01005. PMID: 28871262.Markiewicz I., Lukomska B. The role of astrocytes in the physiology and pathology of the central nervous system. Acta Neurobiol Exp 2006;66(4):343–58. PMID:17265695Talbot K., Turner M.R., Mersden R. et al. Motor neuron disease. A practical manual. New York: Oxford University Press, 2009. 214 p. DOI: 10.1093/ med/9780199547364.003.02.Mamchur V.I., Kravchenko K.A., Oprjshko V.I. Neuropharmacological profile of action glutamatergic drugs (review of literature and own researches). Zhurnal Аkademii medicinskih nauk Ukrainj = Journal of the Academy of Medical Sciences of Ukraine 2009;15(1):50–69. (In Russ.).Мамчур В.И., Кравченко К.А., Опрышко В.И. Нейрофармакологический профиль действия глутаматергических препаратов (обзор литературы и собственных исследований). Журнал Академии медицинских наук Украины 2009;15(1):50–69.Miyaji Y., Yoshimura S., Sakai N. et al. Effect of edaravone on favorable outcome in patients with acute cerebral large vessel occlusion: subanalysis of RESCUE-Japan registry. Neurol Med Chir (Tokyo) 2015;55(3):241–7. DOI: 2176/nmc.ra.20140219. PMID: 25739433.Brooks B.R., Miller R.G., Swash M. et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1(5):293–9. DOI: 10.1080/146608200300079536. PMID: 11464847.Abe K., Aoki M., Tsuji S. et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2017;16(7):505–12. DOI: 10.1016/S14744422(17)30115-1. PMID: 28522181.Mora J.S., Hermine O. Masitinib as an add-on therapy to riluzole is safe and effective in the treatment of amyotrophic lateral sclerosis (ALS). J Neurol Sci 2017;381(10):183. DOI: 10.1016/j.jns.2017.08.526Miller R.G., Block G., Katz J. S. et al. Randomized phase 2 trial of NP001 – a novel immune regulator: safety and early efficacy in ALS. Neurol Neuroimmunol Neuroinflamm 2015;2(3):100. DOI: 10.1212/NXI.0000000000000100. PMID: 25884010.Lunetta C., Lizio A., Maestri E. Serum C-reactive protein as a prognostic biomarker in amyotrophic lateral sclerosis. JAMA Neurol 2017;74(6):660–7. DOI: 10.1001/jamaneurol.2016.6179. PMID: 28384752.Mizuno T., Kurotani T., Komatsu Y. et al. Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology 2004;46(3):404–11. DOI: 10.1016/j.neuropharm.2003.09.009. PMID: 14975696.Brooks B.R., Bravver E., Sanjak M. et al. Adaptive design single center phosphodiesterase type 4 (PDE4) inhibitor – ibudilast (MN-166-ALS-1201) phase 1b/2a clinical trial double-blind (DB) with open label extension (OLE) [NCT02238626] for amyotrophic lateral sclerosis (ALS) patients [1] not requiring non-invasive ventilation (no NIV) up to 5 years (Early Cohort – EC) and [2] requiring non-invasive ventilation (NIV) up to 10 years (advanced NIV cohort – ANC) from disease onset – report of clinical trial DB, OLE and post-treatment cessation epochs – perprotocol (PP) treatment completion associated with improved survival and post treatment cessation loss of muscle strength (P3.127). Neurology 2017;88(16).Ascherio A., LeWitt P.A., Xu K. et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 2009;66(12):1460–8. DOI: 10.1001/archneurol.2009.247. PMID: 19822770.Schwarzschild M.A., Ascherio A., Beal M.F. et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol 2014;71(2):141–50. DOI: 10.1001/jamaneurol.2013.5528. PMID: 24366103.Paganoni S., Zhang M., Quiroz Zárate A. et al. Uric acid levels predict survival in men with amyotrophic lateral sclerosis. J Neurol 2012;259(9):1923–8. DOI: 10.1007/s00415-012-6440-7. PMID: 22323210.Atassi N., Berry J., Shui A. et al. The PRO-ACT database: design, initial analyses, and predictive features. Neurology 2014;83(19):1719–25. DOI: 10.1212/WNL.0000000000000951. PMID: 25298304.Elia A.E., Lalli S., Monsurrò M.R. et al. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur J Neurol 2016;23(1):45-52. PMID: 25664595. DOI: 10.1111/ene.12664.Patten S.A., Aggad D., Martinez. J. et al. Neuroleptics as therapeutic compounds stabilizing neuromuscular transmission in amyotrophic lateral sclerosis. JCI Insight 2017;2(22):e97152. DOI: 10.1172/jci.insight.97152. PMID: 29202456.Patten S.A., Aggad D., Martinez. J. et al. Neuroleptics as therapeutic compounds stabilizing neuromuscular transmission in amyotrophic lateral sclerosis. JCI Insight 2017;2(22):e97152. DOI: 10.1172/jci.insight.97152. PMID: 29202456.Cudkowicz M.E., Shefner J.M., Simpson E. et al. Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis. MuscleNerve 2008;38(1):837-44. DOI: 10.1002/mus.21059. PMID: 18551622.Barral J.M., Broadley S.A., Schaffar G., Hartl F.U. Roles of molecular chaperones in protein misfolding diseases. Semin Cell Dev Biol 2004;15(1):17–29. DOI: 10.1016/j.semcdb.2003.12.010. PMID: 15036203.Kieran D., Kalmar B., Dick J.R. et al. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 2004;10(4):402-5. DOI: 10.1038/nm1021. PMID: 15034571.Benatar M.M., Wuu J., Andersen P.M. et al. Randomized, double-blind, placebocontrolled trial of arimoclomol in rapidly progressive SOD1 ALS Neurology 2018;90(7):565-74. DOI: 10.1212/WNL.0000000000004960. PMID: 29367439.Garnock-Jones K.P. Dextromethorphan/ quinidine: in pseudobulbar affect. CNS Drugs 2011;25(5):435-45. DOI: 10.2165/11207260-000000000-00000. PMID: 21476614.Pioro E.P., Brooks B.R., Cummings J. et al. Safety, Tolerability, and Efficacy Results Trial of AVP-923 in PBA Investigators. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol 2010;68(5):693-702. DOI: 10.1002/ana.22093. PMID: 20839238.Smith R., Pioro E., Myers K. et al. Enhanced bulbar function in amyotrophic lateral sclerosis: the nuedexta treatment trial. Neurotherapeutics 2017;14(3):762-72. DOI: 10.1007/s13311-016-0508-5. PMID: 28070747.Trias E., Ibarburu S., Barreto-Núñez R. et al. Evidence for mast cells contributing to neuromuscular pathology in an inherited model of ALS. JCI Insight 2017;2(20):e95934. DOI: 10.1172/jci.insight.95934. PMID: 29046475.RocheJ.C., Rojas-Garcia R., Scott K. M. et al. A proposed staging system for amyotrophic lateral sclerosis. Brain 2012;135(3):847–52. DOI: 10.1093/brain/awr351. PMID: 22271664.